Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:

Thursday, February 7th, 2008 - 10:20 AM ET:

Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference
Grand Hyatt Hotel

New York City

Monday, February 11, 2008 - 12:30 PM ET:

BIO CEO & Investor Conference

Waldorf=Astoria Hotel

New York City

Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each presentation webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
7. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
8. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
10. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
11. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...n a provocative new study, a University of Utah sc...s the major cause of global warming cannot be st...ociety builds the equivalent of one new nuclear po...here will be any substantial near-term departure f...de emission rates," says the new paper by Tim Garr...
(Date:11/23/2009)...PRNewswire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasd...vember27,2009astheex-dividenddateforits$200million...itizationtransactioncompletedonNovember2,2009.Thed...sofrecordontherecorddate,December1,2009.NASDAQhass...pershareofcommonstockforpurposesoftheex-dividendda...
(Date:11/23/2009)...-ImmuneDesignC or p.(IDC)announcedtodaythatDr.Bruc...erhasasuccessfultrackrec or dinbiotechnologyexecut...ratZymoGenetics,inSeattle,WAandChiefScientificOffi...o: http://www.newscom.com/cgi-bin/prnh/20091123/SF...ecutiveOfficercommented,"IamdelightedtowelcomeDr.B...
(Date:11/23/2009)...-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq: C...iring,developingandcommercializingsignificantprodu...ayannouncedthatCraigA.Collard,PresidentandChiefExe...the21stAnnualPiperJaffrayHealthCareConferenceat3:3...otelinNewYorkCity. ,, Aliveaudioandarchivedwebc...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2
...Management Changes Announced, NEW YORK, March 5 ...nnounced that the company,s Board of Directors,has...chief financial,officer, effective March 31, 2008....recting and managing the company,s fiscal operatio...the organization and its,subsidiaries. Andrew Bonf...
...se II study of 20 patients reported in Annals of O....,(CTI) (Nasdaq: CTIC ; MTA) today announced the ...lts of a limited phase II study of CHOP chemothera...d prednisone) followed by,administration of Zevali...0,years of age or older) with previously untreated...
...lbaum, assistant professor of electrical and compu... received the prestigious Faculty Early Career Dev...n for his pioneering research in the exciting next... This emerging field focuses on harnessing the mag...ctronics ranging from computers to cell phones tha...
Other Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4UD's Appelbaum wins NSF Career Award for research on silicon spintronics 2UD's Appelbaum wins NSF Career Award for research on silicon spintronics 3
(Date:11/24/2009)...rs to understanding how sounds associated with Nav...l or if they hear it at all. , The same type of...ses to detect flaws in the space shuttle,s behemot... peek inside the giant head of a whale. The scans ...of a whale,s hearing anatomy using a breakthrough ...
(Date:11/24/2009)...bby arteries from collapsing have been true life-s...onger needed -- once the arteries are strengthened... no choice but to leave them in place. , Prof. M...t of Biomedical Engineering has developed a new pa...re they,re needed, then dissolves. , "Our new co...
(Date:11/24/2009)... of Medical Toxicology (ACMT) have signed an agree...rnal of Medical Toxicology (JMT), the official jo...s previously published by the University of Pennsy...ogy , an international, peer-reviewed journal, is ... medical toxicology. The quarterly journal focuse...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 1Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 8Carondelet St Marys Medical Plaza II Opens In Tucson 55314 1MicroRNA in human saliva may help diagnose oral cancer 9696 1
...ced a major expansion of a lingua franca used to d...s. The expansion provides terms that scientists c...hen a pathogenic or beneficial microbe encounters ...r developing new interventions for preventing infe...g or encouraging the presence of beneficial microb...
...s of other individuals in order to cooperate in co...we humans take for granted. But, according to evol... Institute in Germany, this ability is present in ...April issue of Current Directions in Psychological... gaze and face orientation to monitor others, beha...
...may explain why Graves?disease (GD) attacks the mu... bulge painfully from their sockets, as in the lat...s Stein Eye Institute and Harbor-UCLA Medical Cent...cells of GD patients?immune systems. Reported Mar... deepen understanding of how the autoimmune disord...
Other Biology News:Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Man's best friend lends insight into human evolution 2UCLA study uncovers clues for why Graves' disease attacks the eyes 2
Viraffinity 100 from Biotech Support Group
Tumor Suppressor Sampler Kit from BD Biosciences Pharmingen
Mouse Anti-Synapsin I Monoclonal Antibody, Unconjugated, Clone 223 from IMGENEX
Slide Chambers from Novagen
Biology Products: